New Genetic Engineering – Small Cause, Big Effect
By Benedikt Haerlin,
ARC2020
| 07. 07. 2023
Adding, removing or swapping individual base pairs in the genome can make a huge difference to the functioning of a cell and the properties of an entire organism. It’s a bit like Johann Sebastian Bach’s definition of skilful piano playing: you just have to press the right key at the right time. It’s that simple, and yet also that difficult. Therein lies the appeal of genetic engineering, but also its risk.
The European Commission is now proposing that plants that have been genetically modified at up to twenty different sites of the genome should nevertheless be “considered equivalent to conventional plants”. At these twenty sites, any number of base pairs (nucleotides) may be deleted or inverted, up to 20 base pairs may be completely altered or replaced, any length of contigous DNA sequences may be replaced by related sequences, and any other alteration of any kind may be made that already occurs in any plant that can be crossed directly with the genetically modified plant or via intermediate steps.
No individual risk assessment and approval would be required for those...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...